Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

WIXOM, Mich., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team will present at two upcoming investor conferences in September:

Rockwell Medical, Inc. to Present at Upcoming September Investor Conferences

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 23.08% and 0.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q2 Loss, Tops Revenue Estimates

Rockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update

WIXOM, Mich., June  10, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the appointment of industry leader and renowned authority on kidney disease, Allen R. Nissenson, M.D., F.A.C.P., to its Board of Directors, effective June 11, 2020. Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp.

Rockwell Medical, Inc. Appoints Dr.

WIXOM, Mich., May  26, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the filing of a New Drug Submission (“NDS”) with Health Canada for Triferic AVNU (ferric pyrophosphate citrate). The Company seeks an indication to promote Triferic AVNU in Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The filing is the first international regulatory submission for the intravenous therapy.

Rockwell Medical, Inc. Files New Drug Submission with Health Canada for Marketing Approval of Triferic® AVNU™

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q1 2020 Results - Earnings Call Transcript

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Rockwell Medical (RMTI) Report Negative Q1 Earnings? What You Should Know

Everi

Geron

Menlo Therapeutics

ORBCOMM

Plug Power

Selecta Biosciences

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

7 Penny Stocks To Buy with Massive Upside Potential

WIXOM, Mich., March  31, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced today the appointment of pharmaceutical industry leader Robert (“Bob”) S. Radie to its Board of Directors, effective March 31, 2020.

Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S.

– Enhances Triferic platform by providing patients with greater access to Rockwell Medical’s innovative therapeutic by expanding administration options for clinicians –

Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients

WIXOM, Mich., March  20, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today reiterated that Medical Resource Acquisition Group LLC (MRAG) failed to properly deliver a notice of director nominations under the Company’s Bylaws within the prescribed advance notice period.

Rockwell Medical, Inc. Confirms Medical Resource Acquisition Group’s Director Nominations Are Invalid

First $22.5 million tranche funded at closing First $22.5 million tranche funded at closing

Rockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC

Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q4 2019 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 8.33% and -6.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates

WIXOM, Mich., March  11, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that its Board of Directors has determined that Medical Resource Acquisition Group LLC (MRAG) failed to properly deliver a notice of director nominations under the Company’s Bylaws within the prescribed advance notice period. As such, their three director nominees will not stand for election at the 2020 annual meeting of stockholders.

Rockwell Medical Determines Medical Resource Acquisition Group’s Director Nominations Are Invalid

No Stockholder Action Required at This Time No Stockholder Action Required at This Time

Rockwell Medical Acknowledges Receipt of Communications from Medical Resource Acquisition Group

-- Continued progress for Triferic® portfolio ---- 77% increase in the number of clinics under contract -- WIXOM, Mich., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today provided a business update and information related to the launch of Dialysate Triferic® (ferric pyrophosphate citrate).

Rockwell Medical, Inc. Provides Business Update

WIXOM, Mich., Feb.  04, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the pricing of its underwritten public offering of 3,191,489 shares of its common stock for gross proceeds of approximately $7.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Rockwell Medical. The offering is expected to close on or about February 6, 2020, subject to customary closing conditions. In addition, Rockwell Medical has granted the underwriter a 30-day option to purchase up to 478,723 additional shares of common stock.

Rockwell Medical Announces Pricing of $7.5 Million Public Offering of Common Stock

WIXOM, Mich., Feb.  03, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced an underwritten public offering of its common stock. In addition, Rockwell Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

Rockwell Medical Announces Proposed Public Offering of Common Stock

- Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually – - Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually –

Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India

WIXOM, Mich., Jan.  09, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced today the appointment of Russell H. Ellison, MD, MSc, to its Board of Directors, effective January 9, 2020.

Rockwell Medical, Inc. Appoints Russell H.

– Company adds experienced medical executive to management team and leading nephrologists to Medical Advisory Board –

Rockwell Medical, Inc. Expands Medical Capabilities

Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q3 2019 Results - Earnings Call Transcript

– Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program –  – Signs leading East Coast academic medical center as first Center of Excellence –

News for Rockwell Medical Stock (RMTI)